$XBIO

Xenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026 2 This communication contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform

Xenetic Biosciences (XBIO) will merge with private Santersus AG in an all-stock deal, creating a Nasdaq-listed company focused on NET-targeting therapies. Existing XBIO shareholders will own 15% of the combined entity, named Santersus Bio (SNTS), while Santersus shareholders get 85%. The merger, expected to close in Q4 2026, combines four clinical programs, including two with FDA Breakthrough Device Designation. The combined company will be led by Santersus CEO James Ladtkow.

Xenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellul

Xenetic Biosciences (NASDAQ:XBIO) reported Q2 2026 results for the quarter ended June 30. Royalty revenue rose about 12% to about $0.7M, while R&D fell about 16% to about $0.6M. G&A increased about 64% to about $1.1M, driving a net loss of about $0.9M. Cash was about $6.5M. The company cited ASCO preclinical/translational data and a PeriNess study approval.

Xenetic Biosciences, Inc. (XBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform Expanded collaborative research initiatives reinforce the Company's long-term DNase deve

Xenetic Biosciences, Inc. has extended its collaboration with The Scripps Research Institute and Dr. Alexey Stepanov for an additional four months to further develop its DNase platform. This collaboration focuses on advancing Xenetic's systemic DNase I candidate, XBIO-015, in combination with CAR T-cell therapies for various cancers, building on preclinical studies that showed significant improvements in reducing tumor burden and extending survival. The company is progressing its DNase-based technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.

While daily stock price moves tend to dominate headlines, shifts in fundamental ranking scores can often tell a deeper story about a company's trajectory. This week, Benzinga's proprietary Growth, Value, Quality and Momentum data revealed major swings among several popular stocks, from biotech to ...

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FRAMINGHAM, MA / ACCESS Newswire / May 14, 2025 / Xenetic Biosciences, Inc. ( NASDAQ:XBIO ) ( "Xenetic" or the "Company" ) , a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for ...